Eli Lilly to double its manufacturing capacity for Mounjaro as it faces financial headwinds going into 2023 — report
Eli Lilly is facing several financial headwinds going into next year, spurred by the drying up of Covid-19 antibody sales and supply constraints, according to a report from SVB Securities by three of its analysts who visited Eli Lilly’s headquarters in Indianapolis last week.
An anticipated “stepdown” in Covid-19 antibody sales, after about $2 billion in recent sales, due to a lack of protection against the newer variants, as well as other speedbumps like Alimta generics, pressure from inflation and incremental costs for manufacturing were cited as potential headwinds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.